A recent randomized, double-blind, placebo-controlled trial suggests that pramipexole, a dopamine agonist with high affinity for the D3 receptor, effectively treats clinically significant anhedonia (loss of interest in previously enjoyable activities) in patients with major depressive disorder, dysthymia, or bipolar depression.

The trial (NCT05355337, NCT05825235) followed 85 participants over 9 weeks. Patients receiving pramipexole as an add-on treatment showed a statistically significant reduction in Snaith-Hamilton Pleasure Scale (SHAPS) scores compared to placebo (mean difference: −4.04; Hedges’ g = 0.62; P=0.006). These clinical improvements were maintained throughout a 6-month open-label extension.

Beyond subjective symptom relief, pramipexole demonstrated objective biological and behavioral signals:

The study advocates for a shift from categorical diagnostic approaches to precision psychiatry focused on specific endophenotypes. By targeting the mesolimbic dopamine pathway, pramipexole provides a targeted strategy for anhedonic depression, a condition that has historically been resistant to conventional antidepressants. The favorable safety profile positions it as a viable augmentation strategy for clinicians managing treatment-resistant mood disorders.

Princeton-based Kardigan has filed an amended S-1 registration statement with the SEC, proposing an IPO of 23.3 million shares priced between $14 and $16 per share. At the upper end of this range, the offering is set to raise $373.3 million, with an additional option for underwriters to push total gross proceeds to approximately $429.3 million.

The primary purpose of this capital raise is to provide the runway necessary to advance the company's clinical-stage pipeline of cardiovascular therapeutics. By shifting from private to public capital, Kardigan aims to accelerate the development of its core heart disease programs through critical clinical milestones.

This filing represents a significant influx of capital into the cardiovascular space, which has seen renewed interest as biotechs move beyond early-stage discovery into late-stage clinical validation. The company’s ability to successfully execute this public offering will be a key indicator of current investor appetite for clinical-stage cardiovascular assets on the Nasdaq.

Novo Nordisk disclosed a cybersecurity incident involving unauthorized access to a limited number of its internal IT systems.  The compromised data includes patient identification numbers (random alphanumeric strings), sex, year of birth, biomarkers, health and immunogenicity data, and various lifestyle factors such as BMI, smoking habits, and alcohol use. The breach also affected a subset of healthcare professionals, with exposed details including names, registration numbers, contact information, and office locations.

Novo Nordisk emphasized that the trial data was pseudonymized and did not contain direct identifiers like patient names. Because the information required to link these records back to individual identities was not part of the compromised datasets, the company does not believe the incident poses an immediate risk to patients. However, the company has advised both patients and healthcare professionals to remain vigilant for potential phishing attempts or suspicious activity.

Novo Nordisk has launched a formal investigation with the assistance of external cybersecurity experts and is coordinating with relevant authorities. As a precautionary measure, the company temporarily took certain internal systems offline to contain the incident and is working to restore them in a controlled and safe manner. Novo Nordisk confirmed that its core business operations, including manufacturing and the supply chain for its commercial products, remain fully functional and unaffected by the incident.

For 20 years, Prix Galien USA has honored the breakthroughs shaping the future of healthcare and improving lives worldwide. Often regarded by the industry as the equivalent of the Nobel Prize of biopharmaceutical research, this is where innovation meets impact.

From groundbreaking therapies to life-saving technologies, this is more than an event, it’s a global movement advancing human health.

Follow The Galien Foundation on LinkedIn to stay updated on announcements, speakers, and innovations leading up to the event.

The Chiesi Group has completed its $1.9 billion acquisition of KalVista Pharmaceuticals, integrating the company into its global Rare Diseases business unit. This move is a strategic play to expand Chiesi’s footprint in specialized therapeutic areas, leveraging KalVista’s expertise to address ultra-rare, high-unmet-need conditions.

Central to the deal is EKTERLY (sebetralstat), the first oral, on-demand therapy approved for hereditary angioedema (HAE) attacks in adults and adolescents. With existing regulatory approvals in the U.S., U.K., E.U., and Japan, the asset offers a significant commercial opportunity as Chiesi works to expand the indication for pediatric populations (ages 2–11) and secures additional global registrations.

By merging KalVista’s proven small-molecule drug discovery platform with Chiesi’s established international infrastructure, the group aims to accelerate the delivery of specialized therapies at scale. This acquisition marks a concerted effort by Chiesi to transition from broader specialty care toward a more concentrated focus on high-value, rare-disease assets, ensuring the company remains competitive in the evolving landscape of orphan drug development.

India’s pharmaceutical industry is undergoing a structural evolution, moving beyond its traditional identity as the "pharmacy of the world" centered on low-cost generics and active pharmaceutical ingredients (APIs). While these segments remain fundamental to global supply chains and economic output, they no longer represent the entirety of the sector's trajectory. The industry is increasingly diversifying its capabilities, aiming to integrate itself into higher-value nodes of the global biopharmaceutical value chain.

This transition is characterized by a deliberate expansion into clinical research, early-stage drug development, and biotechnology. India is steadily positioning itself as a strategic venue for complex clinical trials, translational research, and specialized biopharma services. While the country is not yet a primary originator of novel molecular entities on the global stage, its increasing role in these sophisticated domains suggests a shift toward innovation-led growth. This gradual pivot reflects a maturation of the local ecosystem, as firms leverage their large-scale manufacturing infrastructure and deep scientific talent pool to move toward more complex therapeutic development.